Cargando…

Relationship between somatostatin receptor expressing tumour volume and health‐related quality of life in patients with metastatic GEP‐NET

For patients with gastroenteropancreatic neuroendocrine tumours (GEP‐NET), health‐related quality of life (HRQoL) is important. Meanwhile, whether tumour volume is associated with HRQoL is unknown. Hence, the aim of this study was to assess if total somatostatin receptor expressing tumour volume is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohlsson, Håkan, Gålne, Anni, Trägårdh, Elin, Malmström, Marlene, Sundlöv, Anna, Almquist, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Translational and Clinical Neuroendocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285792/ https://www.ncbi.nlm.nih.gov/pubmed/35488399 http://dx.doi.org/10.1111/jne.13139

Ejemplares similares

AI-based quantification of whole-body tumour burden on somatostatin receptor PET/CT
por: Gålne, Anni, et al.
Publicado: (2023)

Impact of Specific Bowel Symptoms on Quality of Life in Patients with Midgut Neuroendocrine Tumours
por: Ohlsson, Håkan, et al.
Publicado: (2021)

MON-288 TSH Deficiency in Patients on Somatostatin Analog for TSH-PitNET
por: Illouz, Frederic, et al.
Publicado: (2020)

The impact of COVID‐19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients
por: Cives, Mauro, et al.
Publicado: (2022)

PET and PET/CT with (68)Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors
por: Sollini, Martina, et al.
Publicado: (2014)

Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP‐NETs: A Review of Key Issues
por: Anthony, Lowell B., et al.
Publicado: (2021)

Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours
por: Meyer, Tim, et al.
Publicado: (2022)

The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
por: Kim, Seung Tae, et al.
Publicado: (2016)

FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
por: Lacombe, Caroline, et al.
Publicado: (2023)

FRI296 Somatostatin Receptor 5 Staining In Prolactinomas
por: Mehta, Sonal, et al.
Publicado: (2023)

Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module)
por: Ramage, John K., et al.
Publicado: (2022)

Olfactory Neuroblastoma: The Adjunctive Role of Somatostatin Agonists After Surgery
por: Toral, Fernando Pazos, et al.
Publicado: (2021)

Somatostatin, as a Bridge Between the GH-Axis and the Gth-Axis
por: Mizrahi, Naama, et al.
Publicado: (2021)

PMON57 Impact of Injection Modalities on Real-World Injection Experience in Patients with Acromegaly or Neuroendocrine Tumors (NETs) Treated With Somatostatin Analog (SSA) Therapy: Data from the PRESTO 2 Survey
por: Ribeiro-Oliveira, Antonio, et al.
Publicado: (2022)

MON-467 Expression of Somatostatin Receptors in Aggressive Non-Functioning Pituitary Adenomas
por: Soto, Alfonso, et al.
Publicado: (2019)

A Rare Case of Thyrotropin Secreting Pituitary Macroadenoma Primarily Treated With Somatostatin Analogue
por: Elsheikh, Arwa Mahmoud, et al.
Publicado: (2021)

SAT605 Growth Hormone Action In Somatostatin Neurons Regulates Anxiety And Fear Memory
por: dos Santos, Willian O, et al.
Publicado: (2023)

OR01-05 Growth Hormone Action In Somatostatin Neurons Regulates Anxiety And Fear Memory
por: dos Santos, Willian O, et al.
Publicado: (2023)

Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era
por: Kim, Seung Tae, et al.
Publicado: (2016)

The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience
por: Mohamed, Amr, et al.
Publicado: (2023)

OR01-01 Oral, Once-daily, Paltusotine (Non-peptide Selective Somatostatin Receptor Subtype 2 Agonist) Therapy In Patients With Acromegaly Is Associated With Long-term Biochemical And Symptom Control And Is Preferred Over Injectable Somatostatin-Receptor Ligands
por: Gadelha, Monica R, et al.
Publicado: (2023)

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
por: Gordon, Murray B, et al.
Publicado: (2021)

SAT-465 Somatostatin Receptor Ligand as Initial Therapy in a Patient with Pituitary Microadenoma and Acromegaly: Temporary Remission and Recurrence
por: Baby, Ann, et al.
Publicado: (2019)

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Kwekkeboom, D. J., et al.
Publicado: (2003)

GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETs) - APPROACH TO DIAGNOSIS AND MANAGEMENT
por: Oladejo, A.O.
Publicado: (2009)

mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs)
por: Zanini, Sara, et al.
Publicado: (2020)

MON-LB50 Poor Response to Pre-Surgical Treatment With Somatostatin Receptor Ligands Is Associated With Diabetes Mellitus in Patients With Acromegaly
por: Frara, Stefano, et al.
Publicado: (2020)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

OR06-02 TBR-760, a Chimeric Somatostatin-Dopamine Compound, Arrests Aggressive Non-Functioning Pituitary Adenoma Growth In Vivo
por: Halem, Heather A, et al.
Publicado: (2020)

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation
por: Stelmachowska-Banas, Maria, et al.
Publicado: (2021)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

SAT-434 Patient Reported Outcome Data from Acromegaly Patients Treated with Injectable Somatostatin Analogues in Routine Clinical Practice: Preliminary Results
por: Geer, Eliza, et al.
Publicado: (2019)

SAT-439 Impact on Health Care Resources: A Comparison of Costs Following Treatment with Pegvisomant and Somatostatin Analogues Using Optum Claims Database
por: Kelepouris, Nicky, et al.
Publicado: (2019)

Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results From the MPOWERED Trial
por: Biermasz, Nienke, et al.
Publicado: (2021)

A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands
por: Fleseriu, Maria, et al.
Publicado: (2021)

Safety and Efficacy of Switching Injected Peptide Long-Acting Somatostatin Receptor Ligands to Once Daily Oral Paltusotine: ACROBAT Edge Phase 2 Study
por: Gadelha, Monica R, et al.
Publicado: (2021)

RF01 | PMON168 Hedgehog-Induced Somatostatin Receptor Expression is Inhibited by the Activation of the Glucocorticoid Receptor Signaling Pathway in Human Pituitary Adenoma Organoids
por: Zavros, Yana, et al.
Publicado: (2022)

SAT628 Effect Of Hepatic Impairment On The Pharmacokinetics, Safety, And Tolerability Of Oral Paltusotine, A Non-peptide, Selective Somatostatin Receptor Subtype 2 Agonist
por: Luo, Rosa, et al.
Publicado: (2023)

THU064 Clinical, Radiological Characteristics And Response To Somatostatin Analogues Of Acromegaly Patients With Different Patterns Of Growth Hormone Response After Oral Glucose Load
por: Godlewska, Magdalena, et al.
Publicado: (2023)

Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness
por: Barrea, Luigi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g774gnf4o0889fiinu90cj4tes